Protective effects of Apelin-13 on steroid-induced osteonecrosis of the femoral head in rats
- 5 November 2025
- journal article
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 67 (1) , 69-83
Abstract
Osteonecrosis of the femoral head (ONFH) is a debilitating condition characterized by bone tissue necrosis due to vascular insufficiency, often triggered by corticosteroid use. Steroids are commonly employed in the management of autoimmune diseases, organ transplantation, and COVID-19. Early detection is crucial, as ONFH primarily affects young and middle-aged individuals and often progresses to femoral head collapse if untreated. To evaluate the protective effects of Apelin-13 (Ap-13) on steroid-induced ONFH (SONFH) in a rat model. Thirty-two female Sprague-Dawley rats were randomized into four groups: Control, Ap-13 only, ONFH, and ONFH + Ap-13. SONFH was induced using lipopolysaccharide (LPS) and methylprednisolone (MPS). The treatment group received daily intraperitoneal Ap-13 injections. At the fourth week, radiological, histopathological, immunohistochemical, and biochemical analyses were conducted on femoral heads. Micro-CT showed no significant differences in bone mineral density or trabecular parameters. Histopathology revealed increased osteonecrosis, empty lacunae, and vascular thrombosis in the ONFH group, which were significantly reduced in the ONFH + Ap-13 group (p < 0.05). Ap-13 decreased serum malondialdehyde (MDA) levels (p = 0.0002), reduced caspase-3 expression (p < 0.05), and elevated VEGF expression (p = 0.046), indicating reduced oxidative stress, apoptosis, and enhanced vascularization. Additionally, LDL and triglyceride levels were significantly lower in the Ap-13 treated group (p < 0.05). Apelin-13 demonstrates protective effects against SONFH by reducing oxidative stress, apoptosis, and improving vascularization. It may represent a promising noninvasive therapeutic strategy for early-stage ONFH.Keywords
This publication has 45 references indexed in Scilit:
- Tussilagone inhibits osteoclastogenesis by modulating mitochondrial function and ROS production involved Nrf2 activationBiochemical Pharmacology, 2023
- The outcomes of total hip replacement in osteonecrosis versus osteoarthritis: a systematic review and meta-analysisInternational Orthopaedics, 2023
- Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesisBiomedicine & Pharmacotherapy, 2023
- Discovery of the RANKL/RANK/OPG systemJournal of Bone and Mineral Metabolism, 2021
- Animal models of steroid-induced osteonecrosis of the femoral head—a comprehensive research review up to 2018International Orthopaedics, 2018
- Sildenafil improves blood perfusion in steroid-induced avascular necrosis of femoral head in rabbits via a protein kinase G-dependent mechanismActa Orthopaedica et Traumatologica Turcica, 2017
- Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosisInvestigational New Drugs, 2015
- Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female miceBone, 2015
- Bone morphogenetic proteins (BMPs) expression in the femoral heads of patients with avascular necrosisMolecular Biology Reports, 2013
- Divergent Effects of Endogenous and Exogenous Glucocorticoid‐Induced Leucine Zipper in Animal Models of Inflammation and ArthritisArthritis & Rheumatism, 2013